Lakefront Receives Transparency Notification from Bank of AmericaMechelen, Belgium; August 24, 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) received a transparency notification from Bank of America.
U.S. FDA Grants Orphan Drug Designation to Gamgertamig for the Treatment of PemphigusMechelen, Belgium; 24 August 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to gamgertamig for the treatment of pemphigus. Gamgertamig was previously granted both Fast Track and Orphan Drug Designation by the U.S. FDA for the treatment of autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP).
Acquisition of Own SharesMechelen, Belgium; 18 August 2026, 22.01 CET; regulated information
Acquisition of Own SharesMechelen, Belgium; 12 August 2026, 22.01 CET; regulated information
Lakefront Biotherapeutics Reports Half-Year 2026 Financial Results and Provides Business UpdateCompleted acquisition of Ouro Medicines with Gilead Sciences to advance potential first and best-in-class T-cell engager
Acquisition of Own SharesMechelen, Belgium; 04 August 2026, 22.01 CET; regulated information
Acquisition of Own SharesMechelen, Belgium; July 28, 2026, 22.01 CET; regulated information
Acquisition of Own SharesMechelen, Belgium; July 21, 2026, 22.01 CET; regulated information
Acquisition of Own SharesMechelen, Belgium; 14 July 2026, 22.01 CET; regulated information
Lakefront Announces Paulo Fontoura has Resigned from its Board following his Appointment as Global Head of R&D at SanofiMechelen, Belgium; July 13, 2026, 22:01 CET; Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced that following his appointment as Executive Vice President, Global Head of Research & Development Pharma at Sanofi SA, Dr. Paulo Fontoura has tendered his resignation from the Board of Directors.
Acquisition of Own SharesMechelen, Belgium; 07 July 2026, 22.01 CET; regulated information
Acquisition of Own SharesMechelen, Belgium; 30 June 2026, 22.01 CET; regulated information
Lakefront Receives Transparency Notification from Madison Avenue PartnersMechelen, Belgium; June 29, 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) received a transparency notification from Madison Avenue Partners.
Acquisition of Own SharesMechelen, Belgium; 23 June 2026, 22.01 CET; regulated information
Acquisition of Own SharesMechelen, Belgium; June 16, 2026, 22.01 CET; regulated information
Lakefront Announces Initiation of €50 Million Stock Repurchase ProgramMechelen, Belgium; June 9, 2026, 22:01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced the launch of a share repurchase program (the “Program”), under which the Company may repurchase ordinary shares for an aggregate amount of up to €50 Million. Repurchases under the Program may be made no later than December 31, 2026. The Program is entered into with Morgan Stanley & Co International PLC.
Lakefront Appoints Eric Hedrick, MD, as Chief Medical OfficerMechelen, Belgium; June 8, 2026, 22:01 CET; Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced that Eric Hedrick, MD has been appointed Chief Medical Officer. This expanded leadership role supports the Company’s strategic transformation following its acquisition of Ouro Medicines operational assets announced on June 4, 2026.1 Eric will report to Henry Gosebruch, CEO and join the Company’s Management Committee.
GILEAD SCIENCES AND LAKEFRONT COMPLETE ACQUISITION OF OURO MEDICINES TO FURTHER EXPAND INFLAMMATION PIPELINECompanies will collaborate on the development of gamgertamig, a potential first-in-class and best-in-class T cell engager in autoimmune diseases
Lakefront Receives Transparency Notification from Bank of AmericaMechelen, Belgium; May 26, 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) received a transparency notification from Bank of America.
